https://rumahjurnal.or.id/index.php/jim <p><strong>JIM - Journa</strong>l <strong>International</strong> <strong>Multidisciplinary</strong> is published 2 (two) times a year in January and July by the Rahmatan Fiddunya Wal Akhirah Foundation in assisting academics, researchers and practitioners to disseminate their research results. The purpose of the JIM Journal is as a means to publish papers / articles in multidisciplinary science.</p> Rumah Jurnal en-US JIM - Journal International Multidisciplinary 2985-833X <p><strong>JIM - Multidisciplinary International Journa</strong>l provides open access to anyone, ensuring that the information and findings in the article are useful to everyone. This journal article's entire contents can be accessed and downloaded for free. In accordance with the <a href="http://rumahjurnal.or.id/index.php/JEKIN/management/settings/&lt;a%20href=&quot;http:/creativecommons.org/licenses/by-sa/4.0/&quot; rel=&quot;license&quot;&gt;">Creative Commons Attribution-ShareAlike 4.0 International License</a>. </p> <p><a href="http://creativecommons.org/licenses/by-sa/4.0/" rel="license"><img style="border-width: 0;" src="https://i.creativecommons.org/l/by-sa/4.0/88x31.png" alt="Lisensi Creative Commons" /></a><br /><strong>JIM-Multidisciplinary International Journa </strong>is licensed under a <a href="http://creativecommons.org/licenses/by-sa/4.0/">Creative Commons Attribution-ShareAlike 4.0</a></p> https://rumahjurnal.or.id/index.php/jim/article/view/889 <p>Atherosclerosis is an arterial disease often associated with lipids and other metabolic alterations. Various factors are involved in developing atherosclerosis, including Galectin-3 (Gal-3). Pre-clinical studies have shown that Modified Citrus Pectin (MCP), a modified polysaccharide from citrus peels, has the potential of inhibiting Gal-3 and countering the development of atherosclerosis. Thus, this review aims to analyze the role of MCP on inhibiting and regulating Galectin-3 (Gal-3) as an alternative therapeutic target. We examined valid pre-clinical experimental study designs taken from the databases Science Direct, Taylor &amp; Francis, PubMed, and Google Scholar, with publication dates ranging from 2014 to 2024. 15 research articles meet the established inclusion criteria. Our review found that Gal-3 levels rose during atherosclerosis development, triggering proteins that disturbs cardiovascular physiology. Additionally, Gal-3 targeted inhibition using MCP has shown to have therapeutic effects that alleviates hypertrophy and plaque’s size. In essence, MCP emerges as a promising alternative therapy targeting Gal-3 in atherosclerosis progression.</p> Fauzan Syarif Nursyafi Lamirza Rasyid Mikzy Febrian Rivaldi Dwi Putra Hagil Alghufron Renato Dio Kurniawan Copyright (c) 2024 JIM - Journal International Multidisciplinary https://creativecommons.org/licenses/by-sa/4.0 2024-07-31 2024-07-31 2 2 34 42 10.58794/jim.v2i2.889